Adaptive Biotechnologies Corp (ADPT)

Name: Adaptive Biotechnologies Corp (ADPT) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001478320 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated WA
Fiscal year ends Dec 31

For the year ended 2025-12-31, Adaptive Biotechnologies Corp reported revenue of $276.98M. Revenue grew 54.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $308.08M.

Key ratios (year ended 2025-12-31)

74.2%

Gross margin (computed)

-20.6%

Operating margin

-21.5%

Net margin

-27.2%

Return on year-end equity

54.8%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-21

Headquarters locality: Seattle / Seattle · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Revenue	$308.08M	$276.98M	$178.96M	$170.28M	$185.31M	$154.34M	$98.38M	$85.07M	$55.66M	$38.45M
Cost of Revenue	$75.25M	$71.36M	$72.08M	$75.55M	$57.91M	$49.30M	$22.53M	$22.27M	$19.67M	$15.68M
Gross Profit (computed)	$232.83M	$205.62M	$106.88M	$94.72M	$127.40M	$105.04M	$75.85M	$62.80M	$35.99M	$22.77M
R&D Expense	$88.21M	$93.77M	$102.95M	$122.12M	$141.76M	$142.34M	$116.07M	$70.70M	$39.16M	$32.00M
Operating Income	-$37.46M	-$57.12M	-$162.55M	-$227.03M	-$200.19M	-$208.97M	-$152.82M	-$78.39M	-$49.76M	-$44.48M
Depreciation & Amortization	n/a	$16.00M	$17.44M	$19.60M	$20.92M	n/a	n/a	n/a	n/a	n/a
EBITDA	n/a	-$41.12M	-$145.11M	-$207.44M	-$179.27M	n/a	n/a	n/a	n/a	n/a
Net Income	-$63.85M	-$59.50M	-$159.49M	-$225.25M	-$200.19M	-$207.28M	-$146.23M	-$68.61M	-$46.45M	-$42.83M
EPS (Diluted)	n/a	-$0.39	-$1.08	-$1.56	-$1.40	-$1.48	-$1.11	n/a	n/a	n/a
Total Assets	$640.68M	$512.74M	$539.38M	$661.13M	$856.62M	$923.34M	$1.12B	$912.30M	$332.69M	n/a
Total Liabilities	$490.02M	$287.74M	$336.89M	$352.86M	$392.52M	$319.24M	$373.15M	$341.26M	$29.94M	n/a
Shareholders' Equity	$142.91M	$218.79M	$202.71M	$308.40M	$464.17M	$603.99M	$743.27M	$571.04M	-$258.11M	-$224.62M
Cash & Equivalents	$169.87M	$70.50M	$47.92M	$65.06M	$90.03M	$139.06M	$123.44M	$96.58M	$55.03M	n/a
Operating Cash Flow	-$21.01M	-$45.99M	-$95.21M	-$156.32M	-$183.94M	-$192.73M	-$149.68M	$205.40M	-$32.26M	-$34.86M
Capital Expenditures	$3.02M	$2.96M	$3.66M	$10.70M	$16.35M	$61.75M	$18.80M	$11.20M	$6.30M	$2.42M
Free Cash Flow	-$24.03M	-$48.95M	-$98.88M	-$167.02M	-$200.29M	-$254.47M	-$168.49M	$194.20M	-$38.56M	-$37.28M
Shares Outstanding	159.06M	153.78M	147.77M	145.08M	143.11M	141.39M	137.65M	125.24M	12.84M	n/a
Weighted Average Diluted Shares	n/a	151.72M	147.10M	144.38M	142.52M	140.35M	131.22M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.39	-$1.08	-$1.56	-$1.40	-$1.48	-$1.11	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView